Ticker: NRIX

Sanofi extends its licensing agreement with Nurix Therapeutics for the STAT6 program, allowing Nurix to earn up to $465 million. This partnership signals potential long-term value creation amid a competitive biotech landscape, drawing investor attention.

Nurix Therapeutics, Inc. (NASDAQ: NRIX) has reported on its quarterly financial results for the period ending February 28, 2025. Here are the key insights from the latest earnings report: Positive Aspects: Revenue Growth: Collaboration revenue increased to $18.5 million compared to $16.6 million...